~~<i id='EDC9DF0CDC'><strike id='EDC9DF0CDC'><tt id='EDC9DF0CDC'><pre id='EDC9DF0CDC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

comprehensive

author：focus 2025-10-01 02:28:33 - browse：5141

People taking notes while sitting around a meeting table — Adobe

It makes sense in theory for hospitals and startups to strike deals. Not only would doctors get first dibs on new health care technologies, their organizations would see windfalls if those startups hit it big.

In practice, it often doesn’t work out that way. Doctors and other clinicians have their own way of doing things, and they typically don’t take kindly to an administrator telling them to learn a new product, especially if the goal is financial gain.

Several health system-venture capital arrangements have fallen victim to this dynamic — but VC firm General Catalyst said this week it will buy nonprofit Summa Health, anyway.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Astellas still sees hope in its gene therapy after four deaths

focus

knowledge

focus

knowledge

Wikipedia

Forthemanyhigh-achievingperfectionistswhoentermedicalschooleachyear,thestakesoftheirsuccesshavenever

WSS

Obesity now affects over 1 billion people worldwide, study finds

A daunting task: navigating dual Medicare, Medicaid eligibility

ALS groups 'won't be played again' by the FDA, drug sponsors

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

In search for therapies for solid tumors, companies turn to claudin

Change Healthcare cyberattack outage could last weeks

hotspot

comprehensive

focus

Supreme Court strikes down use of affirmative action

How to fix the rural physician shortage in the U.S.

Continuity nursing helped my family in our darkest PICU moments

Biotech companies concerned about China biosecurity crackdown

Sports medicine is finally prioritizing gender equality

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Walensky prepares to leave CDC — and Congress — behind

AstraZeneca loses challenge to Medicare drug price negotiation

Bright Health sells Medicare Advantage business to Molina

Astellas still sees hope in its gene therapy after four deaths

knowledge

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

How to address the problem of discarded donor organs

World's first CRISPR

Surge of respiratory disease in China has likely explanation

PBM reforms clear House panel

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

focus

focus

knowledge

Wikipedia